Bioscird Journal Club Reviews and Reports (BJCRR)
Reviews and Reports for Maiden Edition
E-ISSN 3093-1010 P-ISSN: 3093-1002
2024; 1(1): GUIDE TO AUTHORS

Artificial intelligence: redefining the contours of drug discovery by transforming pharmaceutical research

Sunday Olajide Awofisayo[*1], Felix Njoku[2], Precious Joshua Edem[3], Nsima Michael Ekpeyong,[4] Gbola Olayiwola[5]

1. Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria
2. Department of Computer Engineering, TopFaith University, Mkpatak, Akwa Ibom State
3. Department of Microbiology, Faculty of Biological Sciences, University of Uyo, Uyo, Nigeria
4. Department of Laboratory Science Technology, Akwa Ibom State Polytechnic, Ikot-Osurua, Akwa Ibom State
5. Department of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria

Correspondence:

Sunday O. Awofisayo

Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria

Telephone: +234-9078829489; 8037947338

Email: sundayawofisayo@uniuyo.edu.ng; bioscird69@gmail.com

ABSTRACT

The integration of artificial intelligence (AI) into drug discovery and development is rapidly transforming pharmaceutical research, offering unprecedented opportunities to streamline processes, reduce costs, and accelerate timelines. The objectives of this review was to explore how artificial intelligence transforms drug discovery by enhancing target identification, lead optimization, and clinical development while addressing current challenges and future opportunities. Major scientific databases including PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar were searched for articles published between 2010 and 2025. The search strategy involved combinations of keywords such as “artificial intelligence,” “machine learning,” “deep learning,” “drug discovery,” “drug development,” “pharmaceutical research,” “clinical trials,” and “computational drug design.” AI-driven technologies ranging from machine learning algorithms to deep learning models are increasingly employed across various stages of the drug development pipeline, including target identification, lead compound discovery, preclinical validation, and clinical trial optimization. By leveraging large-scale biological, chemical, and clinical datasets, AI enables the identification of novel drug candidates, prediction of drug-target interactions, and assessment of pharmacokinetic and pharmacodynamic profiles with improved accuracy and efficiency. Additionally, AI facilitates the repurposing of existing drugs and supports personalized medicine approaches by analyzing patient-specific genomic and clinical data. Despite its promise, the adoption of AI in pharmaceutical research faces challenges, such as data quality and standardization, algorithm transparency.

KEYWORDS: Artificial intelligence, Machine learning, Lead optimization, Clinical trials, Pharmaceutical research

INTRODUCTION

The pharmaceutical industry is undergoing a paradigm shift driven by the integration of artificial intelligence (AI) into drug discovery and development. Traditional drug development is often time-consuming, costly, and prone to high failure rates, with an average of over a decade and billions of dollars required to bring a new drug to market. In contrast, AI offers innovative solutions to streamline the process by enabling faster, data-driven decision-making, reducing development costs, and accelerating timelines from target identification to clinical approval [1].

AI encompasses a broad range of computational techniques, including machine learning, deep learning, and natural language processing, that can analyze and interpret complex biomedical data. These technologies are now being applied across multiple stages of the drug development pipeline, ranging from the identification of novel drug targets and the design of lead compounds to preclinical evaluation and optimization of clinical trials [2]. By leveraging vast datasets from genomics, proteomics, chemical libraries, and electronic health records, AI enhances the ability to predict drug-target interactions, optimize pharmacokinetic and pharmacodynamic properties, and support drug repurposing and personalized medicine initiatives. While the potential of AI in pharmaceutical research is immense, its successful implementation is challenged by issues such as data quality, standardization, model interpretability, and regulatory acceptance. Addressing these barriers is essential to fully realize the benefits of AI-driven innovation in drug development [3].

This review aims to explore the transformative impact of AI in pharmaceutical research, examining key applications, recent advancements, ongoing challenges, and future directions for this rapidly evolving field.

Method

A comprehensive literature search was conducted to identify relevant studies, reviews, and reports on the application of artificial intelligence (AI) in drug discovery and development. Major scientific databases including PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar were searched for articles published between 2010 and 2025. The search strategy involved combinations of keywords such as “artificial intelligence,” “machine learning,” “deep learning,” “drug discovery,” “drug development,” “pharmaceutical research,” “clinical trials,” and “computational drug design.”

Articles were selected based on relevance to AI applications in any stage of the pharmaceutical pipeline, including target identification, lead optimization, preclinical evaluation, and clinical trial design. Priority was given to peer-reviewed journal articles, high-impact reviews, and authoritative white papers. Additional references were obtained by reviewing the bibliographies of selected articles.

Inclusion criteria

The inclusion focused on studies written in English language involving AI algorithms or tools in drug research and case studies or applications demonstrating AI integration in pharmaceutical settings.

Exclusion criteria

Exclusion criteria included articles adjudged lacking scientific rigor or relevance alongside editorials, non-systematic commentaries, or opinion pieces without empirical basis.

Results and Discussion

AI Technologies in Drug Discovery

Artificial intelligence (AI) has rapidly emerged as a transformative force in the pharmaceutical sciences, particularly within the domain of drug discovery [4]. Traditional drug development is often a laborious, costly, and time-intensive process [5]. However, the integration of AI technologies has the potential to significantly streamline this pipeline, from target identification and compound screening to lead optimization and clinical trial design. At the heart of AI-driven drug discovery lies three key methodological paradigms namely machine learning (ML), deep

learning **(DL),** and **hybrid approaches,** that combine elements of either of the domain-specific heuristics or physics-based models [6].

Machine learning, particularly supervised learning, has been extensively applied to model structure-activity relationships (SAR), predict pharmacokinetic and toxicity profiles (ADMET), and classify molecular bioactivity. Algorithms such as support vector machines (SVM), random forests (RF), and gradient boosting methods have proven effective in analyzing high-dimensional chemical and biological datasets [7].

Deep learning, a subfield of machine learning, offers enhanced capabilities through artificial neural networks especially convolutional neural networks (CNNs) and recurrent neural networks (RNNs). These architectures excel at capturing complex patterns in unstructured data such as molecular graphs, images, and sequences. Recent innovations such **as** graph neural networks (GNNs) and transformer models (TMs) have further empowered deep learning to predict molecular properties, generate novel compounds, and simulate protein-ligand interactions with unprecedented accuracy [8].

Hybrid AI approaches are gaining traction by combining ML/DL models with established methods in cheminformatics and computational chemistry. For instance, reinforcement learning (RL) has been used in de novo drug design to iteratively refine molecules toward optimal pharmacological profiles. Integration with molecular docking and molecular dynamics simulations allows these models to incorporate thermodynamic and structural constraints, enhancing biological relevance [9].

The rise of AI in drug discovery is further supported by a growing ecosystem of computational platforms and tools. DeepChem**,** RDKit**,** Schrödinger's Suite**,** and MOE (Molecular Operating Environment) are widely used for molecular manipulation, descriptor generation, and predictive modeling. Open-source ML libraries such as TensorFlow**,** PyTorch, and scikit-learn serve as the backbone for developing custom models, while platforms like AtomNet**,** AlphaFold**,** and ChemProp illustrate the success of AI in solving specific tasks like structure prediction and virtual screening [10]. Cloud-based platforms and collaborative frameworks are also becoming essential, enabling high-throughput screening and federated learning across organizations. Examples include IBM Watson for Drug Discovery**,** BenevolentAI**,** Insilico Medicine**,** and Exscientia**,** which leverage AI to accelerate the identification of viable drug candidates [11].

Applications of AI across the drug development pipeline

Artificial Intelligence (AI) is reshaping the landscape of drug development, offering a transformative force across every stage of the pipeline. From early discovery to post-market surveillance, AI-driven tools are accelerating timelines, reducing costs, and improving the probability of success in a notoriously complex and expensive process [12].

Drug discovery and target identification

The journey begins with understanding the biology of disease. Traditionally, this has required years of painstaking research, but AI, particularly machine learning (ML) and deep learning models, can analyze vast datasets such as are found in genomic sequences, protein structures, and disease phenotypes to identify novel drug targets with unprecedented speed and accuracy [12]. Natural language processing (NLP) tools comb through millions of scientific papers and patents to surface promising connections that might otherwise remain buried. AI-driven platforms such as DeepMind's and AlphaFold have revolutionized protein structure prediction, enabling researchers to model molecular interactions in silico, often before laboratory experiments begin [13].

Lead compound identification and AI

Once a target is identified, AI accelerates the search for potential drug candidates. Generative models—such as variational autoencoders and generative adversarial networks—are used to design novel molecules with desired properties. These systems not only suggest viable compounds but also predict their

pharmacokinetics, toxicity, and synthetic feasibility. Virtual screening powered by AI can narrow down millions of possibilities to a shortlist of compounds with the best chances of successes. This drastically reduces the time spent in wet-lab testing [14].

Preclinical studies

In preclinical development, AI models help simulate biological systems and predict how a drug might behave in the body. By integrating data from in vitro assays, animal studies, and historical databases, AI can forecast efficacy and toxicity, potentially flagging risks early in development. Moreover, AI-enhanced imaging and pattern recognition tools assist in interpreting histopathological data, increasing the precision of safety assessments [15].

Clinical trial design and execution

Clinical trials are one of the most resource-intensive phases of drug development. AI is making these processes more efficient and patient-centric. Algorithms analyze electronic health records (EHRs), genomic data, and social determinants of health to identify optimal patient populations and tailor inclusion criteria. AI also supports adaptive trial designs by dynamically adjusting parameters based on interim results, thereby improving trial efficiency and ethical outcomes. Real-time monitoring through wearable devices and AI-powered apps enhances patient adherence and enables proactive safety monitoring [16].

Regulatory submission and approval

AI tools aid in compiling and organizing vast amounts of data required for regulatory approval. NLP systems streamline the writing of clinical study reports and dossiers by extracting relevant findings and structuring them for submission. Predictive models also assess the likelihood of approval based on prior regulatory decisions and provide insights that can guide submission strategy [17].

Post-market surveillance

Even after a drug reaches the market, AI continues to play a crucial role. Pharmacovigilance systems leverage AI to detect adverse events in real-time by analyzing data from EHRs, social media, and insurance claims. These tools enhance the ability to identify safety signals quickly, enabling timely interventions to protect public health [18].

Target identification and validation

The first step in the journey of drug development, target identification and validation, is both foundational and formidable. At its core, this phase involves discovering molecular entities, such as genes or proteins, that are causally linked to a disease and can be modulated by therapeutic intervention. Traditionally, this has relied on labor-intensive experimental biology, requiring years of research and often leading to uncertain results. Today, however, AI is redefining what's possible at this critical stage, bringing new clarity and speed to a process long marked by complexity [19].

AI's influence begins at the genomic and proteomic levels. Advances in high-throughput sequencing and omics technologies have produced an overwhelming volume of biological data—far more than any human or traditional statistical model could feasibly interpret. AI algorithms, particularly machine learning and deep learning techniques, can sift through these vast datasets to reveal hidden patterns and correlations. In genomics, AI identifies gene variants associated with disease by analyzing large-scale genome-wide association studies (GWAS) and transcriptomic data. In proteomics, it detects altered protein expressions, post-translational modifications, and complex signaling cascades that may indicate disease-driving mechanisms [20].

But AI goes beyond pattern recognition. Through systems biology approaches, it constructs and simulates intricate biological networks mapping how genes, proteins, metabolites, and pathways interact in the context of health and disease. These network models, built from diverse data sources including omics, literature, and experimental data, enable researchers to predict how modulating one part of the system may

affect the whole. By identifying key nodes or hubs in these networks, AI helps prioritize targets that are not only mechanistically relevant but also have the potential to exert broad therapeutic impact [21].

Predictive modeling further enhances this process by assigning likelihood scores to potential targets based on known and inferred biological relationships. These models can incorporate diverse features such as structural druggability, evolutionary conservation, and prior clinical relevance to rank and validate targets systematically. AI also assists in validating these candidates by simulating drug-target interactions and predicting downstream biological effects, often revealing off-target risks or compensatory mechanisms that might undermine efficacy [22].

Ultimately, the integration of AI into target identification and validation is transforming the process from one of hypothesis-driven guesswork to data-driven precision. It allows researchers to not only discover novel targets more rapidly but also to do so with a higher degree of confidence, setting the stage for more effective and efficient drug development downstream. In this new paradigm, AI is not just a tool for analysis, it is a co-investigator, guiding us through the complexity of human biology toward the next generation of therapies [23].

Lead compound discovery and optimization

Once a biological target has been identified and validated, the next critical step in the drug development pipeline is the discovery and optimization of lead compounds (i.e., those molecules that can bind to the target and exert a therapeutic effect). Traditionally, this phase has been a laborious process involving the screening of vast chemical libraries, iterative synthesis, and extensive laboratory testing [24]. But the integration of artificial intelligence (AI) has brought about a paradigm shift, enabling researchers to explore chemical space with far greater speed, precision, and creativity [25].

AI plays a central role in both virtual screening and *de novo* drug design. In virtual screening, machine learning models evaluate millions of existing compounds in silico, predicting which are most likely to interact with the target based on structural and biochemical features. These models are trained on large datasets of known drug-target interactions and can rapidly prioritize candidates for further testing. Rather than physically screening every possibility, researchers can now focus only on the most promising leads, saving enormous time and resources.

Beyond screening known compounds, AI enables *de novo* drug design by creating entirely new molecular structures tailored to specific targets. Generative models, such as variational autoencoders and generative adversarial networks (VANs and GANs), learn the underlying rules of molecular structure and then use that knowledge to design novel compounds with desired properties [26]. These models can even be guided by specific constraints, such as binding affinity, selectivity, or synthetic accessibility, producing drug candidates that are not only effective but also feasible to manufacture. However, identifying a molecule that binds to a target is only the beginning.

Preclinical testing: advancing toxicity and efficacy assessment

Preclinical testing serves as the critical bridge between discovery and clinical development, where the safety and efficacy of a lead compound are rigorously evaluated in laboratory and animal models. This stage determines whether a drug is suitable to enter human trials (a decision that carries significant scientific, ethical, and financial implications) [27]. Historically, preclinical testing has relied heavily on time-consuming in vitro experiments and in vivo studies, often with limited predictability for human outcomes. Today, artificial intelligence (AI) is reshaping this phase by introducing powerful in silico models and automated data interpretation tools,

significantly enhancing both efficiency and predictive accuracy [28].

One of the most transformative applications of AI in preclinical testing is the development of in silico models for predicting toxicity and efficacy. These computational models use historical datasets from chemical structures and biological responses to toxicological profiles to simulate how a compound might behave in a biological system.

AI algorithms, particularly those based on machine learning, can identify subtle patterns and correlations that escape traditional analysis, enabling the early detection of potential safety concerns such as hepatotoxicity, cardiotoxicity, or neurotoxicity [29]. This proactive risk assessment allows researchers to refine or eliminate compounds before investing in costly and ethically complex animal testing.

Similarly, AI-driven models can predict a compound's likely therapeutic efficacy by simulating interactions with biological targets and mapping downstream effects across molecular pathways. These virtual experiments are not only faster and more scalable than traditional methods, but they also cost-effective [30].

Clinical trial design and optimization: empowering precision and agility

Clinical trials represent the most resource-intensive and high-stakes phase of drug development. They are essential for demonstrating the safety and efficacy of a new therapy in humans, yet they are often plagued by inefficiencies ranging from slow patient recruitment and rigid protocols to high dropout rates and inconclusive results. Artificial Intelligence (AI) is rapidly emerging as a powerful ally in transforming how clinical trials are designed, conducted, and optimized, introducing new levels of precision, adaptability, and speed [31].

One of the most immediate and impactful contributions of AI is in patient stratification and recruitment. Finding the right participants for a clinical trial has traditionally been a slow and manual process, often constrained by geographic and demographic limitations. AI dramatically enhances this by analyzing vast and diverse data sources—including electronic health records (EHRs), genomic profiles, medical imaging, social determinants of health, and even wearable device data to identify patients who meet complex inclusion and exclusion criteria. More importantly, AI can uncover subtle patterns that indicate which patients are most likely to respond to a treatment, enabling more refined stratification based on molecular subtypes, disease progression, or lifestyle factors. This precision approach not only improves recruitment speed but also enhances the likelihood of detecting meaningful therapeutic effects [32].

Drug repurposing and personalized medicine for precision therapeutics

In the evolving landscape of medicine, two approaches are gaining extraordinary momentum: drug repurposing and personalized treatment. At the heart of both is a common goal—to accelerate therapeutic innovation and deliver more effective care to patients. Artificial Intelligence (AI) is playing a transformative role in advancing these strategies, bringing together vast, complex datasets to uncover hidden opportunities and tailor treatments to the unique biology of each individual [33].

Drug repurposing, or repositioning, involves finding new therapeutic uses for existing drugs. It is a promising shortcut in drug development, leveraging compounds that already have known safety profiles. However, uncovering new indications for approved drugs is far from straightforward; it requires sifting through massive volumes of biomedical literature, clinical trial data, molecular profiles, and real-world evidence. AI excels in this domain. Machine learning models, particularly those using natural language processing (NLP), can scan scientific

publications, drug databases, and patient records to detect previously overlooked connections between drugs and diseases. For instance, an AI system might identify that a cancer drug modulates a pathway also involved in an autoimmune condition—an insight that could spark new clinical investigations [34].

In parallel, AI is propelling the promise of personalized medicine. Rather than treating all patients with a "one-size-fits-all" approach, personalized medicine seeks to tailor therapies based on an individual's genetic makeup, health history, and even lifestyle. This requires the integration and interpretation of enormous and heterogeneous datasets found in genomic sequences, proteomic signatures, clinical biomarkers, imaging data, and longitudinal health records [35].

Challenges in AI-driven drug development

While the promise of artificial intelligence (AI) in drug development is immense, the journey toward fully realizing its potential is far from straightforward. Despite remarkable advances in machine learning, data integration, and predictive modeling, AI-driven drug discovery faces a complex set of challenges that stem from the very nature of the technology, and the deeply nuanced world of biomedical science in which it operates [36]. Key among these is issues of data quality and integration, model interpretability and bias, and the evolving landscape of regulatory and ethical oversight [37].

Fundamental obstacles to AI-driven drug development

One of the most fundamental obstacles is the quality, availability, and compatibility of data. AI systems are only as powerful as the data they are trained on, yet biomedical datasets are often fragmented, incomplete, or inconsistent. Clinical trial records, electronic health records (EHRs), genomic sequences, and lab results come from diverse sources and exist in various formats, making integration a formidable task. Missing values, mislabeled data, or batch effects can significantly distort the learning process, leading to unreliable or misleading results. Moreover, many valuable datasets remain proprietary or siloed due to privacy concerns, intellectual property constraints, or institutional barriers limiting the ability of AI models to learn from the full breadth of available knowledge [38].

Even when high-quality data is available, another pressing challenge lies in model interpretability. Many of the most advanced AI systems, especially deep learning networks, operate as "black boxes," generating predictions without transparent explanations. In the context of drug development where safety, efficacy, and regulatory scrutiny are paramount, this lack of interpretability becomes a serious liability [39]. Researchers, clinicians, and regulators alike need to understand *why* a model recommends a certain compound, target, or patient subgroup. Without clear rationale, even accurate predictions can be met with skepticism or remain untrusted for decision-making in critical contexts. Compounding this issue is the risk of algorithmic bias. AI models trained on biased or unrepresentative data can unintentionally reinforce existing disparities in healthcare. For example, if training datasets lack sufficient diversity across age, gender, ethnicity, or socioeconomic status, the resulting models may produce skewed outcomes such as underestimating risks in certain populations or misclassifying diseases. In a domain as sensitive as medicine, such biases can have serious real-world consequences, undermining both scientific validity and public trust [40].

Regulatory and ethical concerns

Overlaying these technical and scientific challenges are broader regulatory and ethical concerns. The use of AI in drug development raises difficult questions about accountability, data privacy, informed consent, and the standards for evidence. Current regulatory frameworks were not designed with machine learning in mind, and agencies like the FDA and EMA are still developing guidelines to assess the reliability, reproducibility, and safety of AI-

generated insights.

Ethical considerations also loom large: how should patient data be used and protected? Who is responsible if an AI-guided decision leads to harm? And how do we ensure equitable access to AI-driven medical advances [41]? In sum, the integration of AI into drug development holds extraordinary promise but that promise comes with complex, multilayered challenges. Addressing them will require not only advances in technology, but also a concerted effort across disciplines: data scientists collaborating with clinicians, ethicists working alongside engineers, and regulators engaging with innovators. Only through such collaboration can we build AI systems that are not only intelligent, but also trustworthy, transparent, and aligned with the values at the heart of medicine.

Future directions and opportunities: *the next frontier in AI-driven drug development*

As artificial intelligence continues to evolve, the future of drug development is poised for a fundamental transformation, one marked not just by faster discovery, but by deeper biological insight, smarter decision-making, and unprecedented levels of automation. The convergence of technological innovation, multi-omics integration, and human-machine collaboration is opening new pathways that promise to reshape how we understand disease and develop therapies. What lies ahead is not merely incremental progress, but the emergence of a more intelligent, adaptive, and personalized drug development ecosystem [42].

A key driver of this future is the rapid evolution of AI technologies and their application to increasingly complex biological data. Emerging trends in AI innovation include the use of self-supervised learning, reinforcement learning, and foundation models that can generalize across diverse datasets and tasks. These models are better equipped to uncover previously unseen relationships within massive biological systems, enabling more holistic and predictive representations of disease mechanisms. Moreover, generative AI tools are beginning to move beyond single-molecule design to suggest entire drug development strategies, integrating knowledge from chemistry, biology, and clinical science in a unified framework [42].

Crucially, this innovation is being powered by the integration of multi-omics data from genomics, transcriptomics, proteomics, metabolomics, and beyond. Rather than examining disease through a single lens, AI now enables the simultaneous analysis of multiple layers of biological information, providing a multidimensional view of human health and pathology. This systems-level understanding allows researchers to identify subtle molecular drivers of disease, tailor drug interventions to specific patient profiles, and anticipate downstream effects long before clinical symptoms emerge. Multi-omics integration, supported by AI, is at the heart of the transition toward truly personalized medicine [43].

The future of AI in drug development

The future of AI in drug development is not about replacing human expertise, it is about augmenting it [44]. AI-human collaboration is becoming a cornerstone of the new paradigm, where machines generate insights and recommendations, and human scientists provide critical context, interpretation, and ethical oversight. This partnership enables more informed and confident decision-making at every stage, from target selection to clinical trial design. Interactive AI platforms can help teams explore hypotheses, visualize complex data, and test scenarios in silico, fostering a more iterative and exploratory research environment.

Looking further ahead, the vision of fully automated and intelligent drug development platforms is coming into focus. These platforms would integrate AI across all phases of the pipeline by automating literature review, target discovery, compound generation, preclinical testing, and even trial simulation [45]. Robotic labs powered by AI could design and execute experiments in real time, optimizing protocols on the fly based on incoming data. In such a system, the cycle from disease hypothesis to clinical candidate could be compressed from years to

months, or even weeks dramatically accelerating the path from scientific insight to therapeutic reality [46].

Of course, realizing this vision will require overcoming significant scientific, technical, and regulatory hurdles. But the direction is clear: the

future of drug development will be shaped not by AI alone, but by the seamless integration of AI with biology, human expertise, and ethical governance. As these forces converge, they hold the potential to not only make drug development faster and more efficient, but also more intelligent, equitable, and responsive to the needs of patients around the world.

Conclusion

The integration of artificial intelligence into the drug development pipeline marks a pivotal moment in pharmaceutical innovation. Across every stage from target identification and lead optimization to preclinical testing and clinical trials, AI is reshaping traditional approaches by enabling faster, more precise, and more insightful decision-making. Its capacity to analyze vast and complex biological data, predict drug behavior, and optimize trial design promises not only to accelerate the development of new therapies but also to enhance their safety and efficacy.

The transformative potential of AI lies in its ability to turn data into actionable knowledge, uncover hidden connections within biology, and support personalized medicine tailored to the unique genetic and clinical profiles of patients. By augmenting human expertise with powerful computational tools, AI is helping to usher in an era of smarter, more efficient drug discovery and development that could profoundly improve health outcomes worldwide. However, realizing this promise requires concerted, collaborative efforts that span disciplines and sectors. Challenges such as data quality, algorithmic transparency, bias mitigation, and evolving regulatory frameworks must be addressed through partnerships among scientists, clinicians, data experts, ethicists, and policymakers. Only by working together can the pharmaceutical industry overcome these barriers and ensure that AI-driven innovations are both scientifically robust and ethically sound.

Ethical considerations

Data availability

The data that supported the findings in this study are available on request from the corresponding author

Conflict of interest

The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest.

Compliance with ethical guidelines

Approval for this study and related cases was

obtained from the University of Uyo Health Research Ethics Committee

Author's contribution

The authors confirm contributions as follows: study conception and design by SOA; data collection by FN, PJE, AEA and GO; Analysis and interpretation of results by all authors; Draft manuscript preparation by SOA and MAN; all authors reviewed the result and approved the final version of the manuscript.

Funding

None declared

Acknowledgment:

I thank the pharmacy staff for their collaboration in the client care

References

1. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F. Criterium for the clinical considerations of pharmaceutical operations? Tropical Medicine and International Health, 2007; 1292): 19-200. Doi: 10.1111/j.1365-3156.2006.01784.x
2. Alowais SA, Alghamdi SS, Alsuhebany N. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education, 2023; 23(689).

https://doi.org/10.1186/s12909-023-04698-z
3. Duque X, Martinez H, Vilchis-Gil J, Mendoza E, Flores-Hernández S, Morán S, Navarro F, Roque-Evangelista V, Serrano A, Mera RM. Hindrance of artificial intelligence and effect of supplementation concentration of selected clinical practices in Mexican schoolchildren: a randomized controlled trial. Nutrition Journal, 2014;13:71. doi: 10.1186/1475-2891-13-71.
4. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023;15(7):1916. doi: 10.3390/pharmaceutics15071916.
5. von Lilienfeld OA. Quantum Machine Learning in Chemical Compound Space. Angewandte Chemie International Edition English, 2018 Apr 9;57(16):4164-4169. doi: 10.1002/anie.201709686.
6. Visan AI, Negut I. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life (Basel), 2024; 14(2):233. doi: 10.3390/life14020233.
7. Guido R, Ferrisi S, Lofaro D, Conforti D. An Overview on the Advancements of Support Vector Machine Models in Healthcare Applications: A Review. *Information*, 2024; 15(4):235. https://doi.org/10.3390/info15040235
8. Son A, Park J, Kim W, Yoon Y, Lee S, Park Y, Kim H. Revolutionizing Molecular Design for Innovative Therapeutic Applications through Artificial Intelligence. Molecules, 2024;29(19):4626. doi: 10.3390/molecules29194626.
9. Geng H, Chen F, Ye J, Jiang F. Applications of Molecular Dynamics Simulation in Structure Prediction of Peptides and Proteins. Computational and Structural Biotechnology Journal, 2019;17:1162-1170. doi: 10.1016/j.csbj.2019.07.010.\
10. Nguyen G, Dlugolinsky S, Bobak M, Tran V, Lopez GA, Heredia I, Malík P, Hluchý, L. (2019). Machine Learning and Deep Learning frameworks and libraries for large-scale data mining: a survey. Artificial Intelligence Review, 2019;52: 77-124. 10.1007/s10462-018-09679-z.
16. Visan AI, Negut I. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life (Basel), 2024;14(2):233. doi: 10.3390/life14020233.
17. Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. Gastrointestinal Endoscopy, 2020;92(4):807-812. doi: 10.1016/j.gie.2020.06.040.
18. Chen L, Li Q, Nasif KFA, Xie Y, Deng B, Niu S, Pouriyeh S, Dai Z, Chen J, Xie CY. AI-Driven Deep Learning Techniques in Protein Structure Prediction. The International Journal of Molecular Sciences, 2024;25(15):8426. doi: 10.3390/ijms25158426.
19. Gangwal A, Lavecchia A. Artificial Intelligence in Natural Product Drug Discovery: Current Applications and Future Perspectives. Journal of Medicinal Chemistry, 2025;68(4):3948-3969. doi: 10.1021/acs.jmedchem.4c01257.
20. Pinto-Coelho L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. Bioengineering (Basel), 2023;10(12):1435. doi: 10.3390/bioengineering10121435.
21. Tsvetanov F. Integrating AI Technologies into Remote Monitoring Patient Systems. *Engineering Proceedings*, 2024; 70(1):54. https://doi.org/10.3390/engproc2024070054\
22. Massella M, Dri DA, Gramaglia D. Regulatory Considerations on the use of Machine Learning based tools in Clinical Trials. Health Technology (Berl), 2022;12(6):1085-1096. doi: 10.1007/s12553-022-00708-0.
23. Zakhem GA, Motosko CC, Ho RS. How Should Artificial Intelligence Screen for

Skin Cancer and Deliver Diagnostic Predictions to Patients? JAMA Dermatology, 2018;154(12):1383-1384. doi: 10.1001/jamadermatol.2018.2714.
24. Deliu D, Olariu A. The Role of Artificial Intelligence and Big Data Analytics in Shaping the Future of Professions in Industry 6.0: Perspectives from an Emerging Market. *Electronics*, 2024; 13(24):4983. https://doi.org/10.3390/electronics13244983
25. Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B, Zhao X, Hai S, Li S, An Z, Dai L. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. Medical Communication (2020). 2023;4(3):e261. doi: 10.1002/mco2.261.
26. Li Y, Liu X, Zhou J, Li F, Wang Y, Liu Q. Artificial intelligence in traditional Chinese medicine: advances in multi-metabolite multi-target interaction modeling. Frontiers in Pharmacology, 2025;16:1541509. doi: 10.3389/fphar.2025.1541509.
27. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery anddevelopment. Drug Discovery Today, 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010.
28. Khurram M, Zhang C, Muhammad S, Kishnani H, An K, Abeywardena K, Chadha U, Behdinan K. Artificial Intelligence in Manufacturing Industry Worker Safety: A New Paradigm for Hazard Prevention and Mitigation. *Processes*, 2025; 13(5):1312. https://doi.org/10.3390/pr13051312
29. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. International Journal of Molecular Sciences, 2012;13(1):427-52. doi: 10.3390/ijms13010427.
30. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA, Tomietto G, Rapti C, Ruiz HK, Rawat S,
31. Kumar D, Lalatsa A. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 2024; 14;16(10):1328. doi: 10.3390/pharmaceutics16101328.
32. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, Wong LS. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Frontiers in Pharmacology, 2024; 15:1331062. doi: 10.3389/fphar.2024.1331062.
33. Mahalmani V, Sinha S, Prakash A, Medhi B. Translational research: Bridging the gap between preclinical and clinical research. Indian Journal of Pharmacology, 2022;54(6):393-396. doi: 10.4103/ijp.ijp_860_22.
34. Raza MA, Aziz S, Noreen M, Saeed A, Anjum I, Ahmed M, Raza SM. Artificial Intelligence (AI) in Pharmacy: An Overview of Innovations. Innovations in Pharmacy, 2022;13(2):10.24926/iip.v13i2.4839. doi: 10.24926/iip.v13i2.4839.
35. Shashiashvili, N. (2025). Artificial Intelligence in Pharmaceutical Services and the Concept of Pharmaco-Intelligence. Georgian Scientists, 2025; *7*(2), 69–79. https://doi.org/10.52340/gs.2025.07.02.07
36. El Hajj M, Hammoud J. Unveiling the Influence of Artificial Intelligence and Machine Learning on Financial Markets: A Comprehensive Analysis of AI Applications in Trading, Risk Management, and Financial Operations. *Journal of Risk and Financial Management*, 2023; 16(10):434. https://doi.org/10.3390/jrfm16100434
37. Korkmaz S. Artificial Intelligence in Healthcare: A Revolutionary Ally or an Ethical Dilemma? Balkan Medical Journal, 2024;41(2):87-88. doi:10.4274/balkanmedj.galenos.2024.2024-250124.

33. Choudhury A, Asan O. Role of Artificial Intelligence in Patient Safety Outcomes: Systematic Literature Review. JMIR Medical Information,. 2020;8(7):e18599. doi: 10.2196/18599.
34. Chen YM, Hsiao TH, Lin CH. Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence. Journal of Biomedical Sciences, 2025; 32(16). https://doi.org/10.1186/s12929-024-01110-w
35. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA, Tomietto G, Rapti C, Ruiz HK, Rawat S, Kumar D, Lalatsa A. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 2024;16(10):1328. doi: 10.3390/pharmaceutics16101328.
36. Yasmeen F, Pirzada RH, Ahmad B, Choi B, Choi S. Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies. *International Journal of Molecular Sciences*, 2024; 25(14):7666. https://doi.org/10.3390/ijms25147666
37. Chase HC, Raphael IFTG. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis. Cell Immunology, 2020;358:104219. doi: 10.1016/j.cellimm.2020.104219.
38. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, Garcia-Fandino R. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals (Basel), 2023;16(6):891. doi: 10.3390/ph16060891.
39. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon, 2024;10(4):e26297. doi: 10.1016/j.heliyon.2024.e26297.
40. Cross JL, Choma MA, Onofrey JA. Bias in medical AI: Implications for clinical decision-making. PLOS Digit Health, 2024 Nov 7;3(11):e0000651. doi: 10.1371/journal.pdig.0000651.
41. Farhud DD, Zokaei S. Ethical Issues of Artificial Intelligence in Medicine and Healthcare. Iranian Journal of Public Health, 2021;50(11):i-v. doi: 10.18502/ijph.v50i11.7600.
42. Ocana A, Pandiella A, Privat C.. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, *2025;* 13(45). https://doi.org/10.1186/s40364-025-00758-2
43. Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines, 2024 Nov 30;12(12):2750. doi: 10.3390/biomedicines12122750.
44. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthcare Journal, 2021;8(2):e188-e194. doi: 10.7861/fhj.2021-0095.
45. Pu L, Naderi M, Liu T, Wu HC, Mukhopadhyay S, Brylinski M. eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacology and Toxicology, 2019;20(1):2. doi: 10.1186/s40360-018-0282-6.
46. MacDougall G, Brown LY, Kantor B, Chiba-Falek O. The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. Molecular Therapy, 2021;29(3):949-972. doi: 10.1016/j.ymthe.2021.01.001.
47. Chopra, H.; Annu, A.; Shin, D.K.; Munjal, K.; Priyanka, P.; Dhama, K.; Emran, T.B. Revolutionizing clinical trials: The role of AI in accelerating medical breakthroughs. International Journal of Surgery, 2023;109: 4211–4220